General Information of Drug (ID: DML6PO5)

Drug Name
GM-CSF cancer vaccine Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DML6PO5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting GMCSFR-alpha (CSF2RA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sargramostim DMY0M8J Bone marrow transplantation QB63.6 Approved [3]
B-cell lymphoma vaccine DMBRFUQ Follicular lymphoma 2A80 Preregistration [4]
Pixykine DMCA6BW Human immunodeficiency virus infection 1C62 Phase 3 [5]
Molgramostim DM2TNJ1 Autoimmune pulmonary alveolar proteinosis CB04.31 Phase 3 [6]
AFTVac DMD3XMG Glioblastoma multiforme 2A00.0 Phase 2 [7]
Mavrilimumab DMMVFRC Rheumatoid arthritis FA20 Phase 2 [8]
Leukemia cancer vaccine DMIFGLY Acute myeloid leukaemia 2A60 Phase 2 [2]
Myeloma cancer vaccine DMO1XUK Multiple myeloma 2A83 Phase 2 [2]
MOR-103 DMXVIQN Multiple sclerosis 8A40 Phase 1/2 [9]
KH-901 DMR14VE Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GMCSFR-alpha (CSF2RA) TT6MP2Z CSF2R_HUMAN Not Available [2]

References

1 A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas. Journal of Clinical Oncology, Vol 25, No 18S (June 20 Supplement), 2007: 3010.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
3 Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9.
4 Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2.
5 Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7.
6 Clinical pipeline report, company report or official report of gensci-china.
7 Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
8 Clinical pipeline report, company report or official report of MedImmune (2011).
9 MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64.
10 Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):386-90.